Human equilibrative nucleoside transporter 1 predicts survival in patients with pancreatic cancer treated with gemcitabine: A meta-analysis

Genetic Testing and Molecular Biomarkers

Volumn 18, Issue 5, 2014, Pages 306-312

  Zhu, Yufeng ^a   Qi, Ming ^a   Lao, Lijun ^a   Wang, Wei ^a   Hua, Luojie ^a   Bai, Guang ^a  

^a JINZHOU MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; GEMCITABINE; TUMOR MARKER; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE;

ARTICLE; BIBLIOGRAPHIC DATABASE; CANCER PROGNOSIS; CANCER SURVIVAL; CBM DATABASE; COCHRANE LIBRARY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; EMBASE; GENE EXPRESSION; HUMAN; MEDLINE; META ANALYSIS; OVERALL SURVIVAL; PANCREAS CANCER; SYSTEMATIC REVIEW; TREATMENT OUTCOME; WEB OF SCIENCE; ANALOGS AND DERIVATIVES; METABOLISM; PANCREATIC NEOPLASMS; PATHOPHYSIOLOGY; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; EQUILIBRATIVE NUCLEOSIDE TRANSPORTER 1; HUMANS; PANCREATIC NEOPLASMS; SURVIVAL RATE;

EID: 84899826312     PISSN: 19450265     EISSN: 19450257     Source Type: Journal    
DOI: 10.1089/gtmb.2013.0419     Document Type: Article

References (44)

1. Biggerstaff BJ, Jackson D (2008) The exact distribution of Cochran's heterogeneity statistic in one-way random effects meta-analysis. Stat Med 27:6093-6110
2. Borbath I, Verbrugghe L, Lai R, et al. (2012) Human equilibrative nucleoside transporter 1 (hENT1) expression is a potential predictive tool for response to gemcitabine in patients with advanced cholangiocarcinoma. Eur J Cancer 48: 990-996
3. Choi M, Kim R, Saif MW (2012) What options are available for refractory pancreatic cancer? JOP 13:163-165
4. Conroy T, Desseigne F, Ychou M, et al. (2011) FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med 364:1817-1825
5. Farrell JJ, Elsaleh H, Garcia M, et al. (2009) Human equilibrative nucleoside transporter 1 levels predict response to gemcitabine in patients with pancreatic cancer. Gastroenterology 136:187-195
6. Fujita H, Ohuchida K, Mizumoto K, et al. (2010) Gene expression levels as predictive markers of outcome in pancreatic cancer after gemcitabine-based adjuvant chemotherapy. Neoplasia 12:807-817
7. Garcia-Manteiga J, Molina-Arcas M, Casado FJ, et al. (2003) Nucleoside transporter profiles in human pancreatic cancer cells: role of hCNT1 in 2,2-difluorodeoxycytidine-induced cytotoxicity. Clin Cancer Res 9:5000-5008
8. Giovannetti E, Del Tacca M, Mey V, et al. (2006) Transcription analysis of human equilibrative nucleoside transporter-1 predicts survival in pancreas cancer patients treated with gemcitabine. Cancer Res 66:3928-3935
9. Hsu CC, Herman JM, Corsini MM, et al. (2010) Adjuvant chemoradiation for pancreatic adenocarcinoma: the Johns Hopkins Hospital-Mayo Clinic collaborative study. Ann Surg Oncol 17:981-990
10. Jackson D,White IR, Riley RD (2012) Quantifying the impact of between-study heterogeneity in multivariate meta-analyses. Stat Med 31:3805-3820
11. Kanai M, Yoshimura K, Asada M, et al. (2011) A phase I/II study of gemcitabine-based chemotherapy plus curcumin for patients with gemcitabine-resistant pancreatic cancer. Cancer Chemother Pharmacol 68:157-164
12. Kim R, Tan A, Lai KK, et al. (2011a) Prognostic roles of human equilibrative transporter 1 (hENT-1) and ribonucleoside reductase subunit M1 (RRM1) in resected pancreatic cancer. Cancer 117:3126-3134
13. Kim ST, Lim do H, Jang KT, et al. (2011b) Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther 10:1993-1999
14. Kondo N, Murakami Y, Uemura K, et al. (2012) Combined analysis of dihydropyrimidine dehydrogenase and human equilibrative nucleoside transporter 1 expression predicts survival of pancreatic carcinoma patients treated with adjuvant gemcitabine plus S-1 chemotherapy after surgical resection. Ann Surg Oncol 19 Suppl 3:S646-S655
15. Kovacevic Z, Chikhani S, Lovejoy DB, et al. (2011) Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer. Mol Pharmacol 80:598-609
16. Lai R, Bartlett NL, Mackey JR, et al. (2008) High expression of nucleoside transporter protein hENT1 in Reed-Sternberg cells is associated with treatment failure in relapsed/refractory Hodgkin lymphoma patients treated with gemcitabine, vinorelbine and liposomal doxorubicin- A CALGB 59804 correlative study. Leuk Lymphoma 49:1202-1205
17. Lau MK, Davila JA, Shaib YH (2010) Incidence and survival of pancreatic head and body and tail cancers: a population-based study in the United States. Pancreas 39:458-462
18. Li D, Xie K, Wolff R, et al. (2004) Pancreatic cancer. Lancet 363:1049-1057
19. Marechal R, Bachet JB, Mackey JR, et al. (2012) Levels of gemcitabine transport and metabolism proteins predict survival times of patients treated with gemcitabine for pancreatic adenocarcinoma. Gastroenterology 143:664-674; e661-e666
20. Marechal R, Mackey JR, Lai R, et al. (2009) Human equilibrative nucleoside transporter 1 and human concentrative nucleoside transporter 3 predict survival after adjuvant gemcitabine therapy in resected pancreatic adenocarcinoma. Clin Cancer Res 15:2913-2919
21. Michalski CW, Erkan M, Sauliunaite D, et al. (2008) Ex vivo chemosensitivity testing and gene expression profiling predict response towards adjuvant gemcitabine treatment in pancreatic cancer. Br J Cancer 99:760-767
22. Mori R, Ishikawa T, Ichikawa Y, et al. (2007) Human equilibrative nucleoside transporter 1 is associated with the chemosensitivity of gemcitabine in human pancreatic adenocarcinoma and biliary tract carcinoma cells. Oncol Rep 17:1201-1205
23. Morinaga S, Nakamura Y, Watanabe T, et al. (2012) Immunohistochemical analysis of human equilibrative nucleoside transporter-1 (hENT1) predicts survival in resected pancreatic cancer patients treated with adjuvant gemcitabine monotherapy. Ann Surg Oncol 19 Suppl 3:S558-S564
24. Murata Y, Hamada T, Kishiwada M, et al. (2012) Human equilibrative nucleoside transporter 1 expression is a strong independent prognostic factor in UICC T3-T4 pancreatic cancer patients treated with preoperative gemcitabinebased chemoradiotherapy. J Hepatobiliary Pancreat Sci 19: 413-425
25. Nakagawa N, Murakami Y, Uemura K, et al. (2013) Combined analysis of intratumoral human equilibrative nucleoside transporter 1 (hENT1) and ribonucleotide reductase regulatory subunit M1 (RRM1) expression is a powerful predictor of survival in patients with pancreatic carcinoma treated with adjuvant gemcitabine-based chemotherapy after operative resection. Surgery 153:565-575
26. Nakahira S, Nakamori S, Tsujie M, et al. (2008) Pretreatment with S-1, an oral derivative of 5-fluorouracil, enhances gemcitabine effects in pancreatic cancer xenografts. Anticancer Res 28:179-186
27. Nakata B, Amano R, Nakao S, et al. (2010) Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer. J Exp Clin Cancer Res 29:15
28. Neoptolemos JP, Stocken DD, Bassi C, et al. (2010) Adjuvant chemotherapy with fluorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial. JAMA 304:1073-1081
29. Oettle H, Post S, Neuhaus P, et al. (2007) Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA 297:267-277
30. Peters JL, Sutton AJ, Jones DR, et al. (2006) Comparison of two methods to detect publication bias in meta-analysis. JAMA 295:676-680
31. Pliarchopoulou K, Pectasides D (2009) Pancreatic cancer: current and future treatment strategies. Cancer Treat Rev 35:431-436
32. Robins MJ, Peng Y, Damaraju VL, et al. (2010) Improved syntheses of 5-S-(2-aminoethyl)-6-N-(4-nitrobenzyl)-5-thioadenosine (SAENTA), analogues, and fluorescent probe conjugates: analysis of cell-surface human equilibrative nucleoside transporter 1 (hENT1) levels for prediction of the antitumor efficacy of gemcitabine. J Med Chem 53:6040-6053
33. Seufferlein T (2013) Systemic treatment of advanced pancreatic cancer-step by step progress. Gut 62:660-661
34. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10-29
35. Song H, Han B, Park CK, et al. (2013) Phase II trial of gemcitabine and S-1 for patients with advanced pancreatic cancer. Cancer Chemother Pharmacol 72:845-852
36. Spratlin J, Sangha R, Glubrecht D, et al. (2004) The absence of human equilibrative nucleoside transporter 1 is associated with reduced survival in patients with gemcitabine-treated pancreas adenocarcinoma. Clin Cancer Res 10:6956-6961
37. Stang A (2010) Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol 25:603-605
38. Tempero MA, Berlin J, Ducreux M, et al. (2011) Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol 22:1500-1506
39. Traverso LW (2006) Pancreatic cancer: surgery alone is not sufficient. Surg Endosc 20 Suppl 2:S446-S449
40. Ueno H, Okusaka T, Furuse J, et al. (2011) Multicenter phase II study of gemcitabine and S-1 combination therapy (GS Therapy) in patients with metastatic pancreatic cancer. Jpn J Clin Oncol 41:953-958
41. Van Laethem JL, Hammel P, Mornex F, et al. (2010) Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study. J Clin Oncol 28:4450-4456
42. Voutsadakis IA (2011) Molecular predictors of gemcitabine response in pancreatic cancer. World J Gastrointest Oncol 3:153-164
43. Wang Z, Li Y, Kong D, et al. (2009) Acquisition of epithelialmesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway. Cancer Res 69:2400-2407
44. Wonganan P, Chung WG, Zhu S, et al. (2012) Silencing of ribonucleotide reductase subunit M1 potentiates the antitumor activity of gemcitabine in resistant cancer cells. Cancer Biol Ther 13:908-914.